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Introduction
The human body depends on an integrated neuro-en-
docrine response in order to adapt to external and internal
stressors. In critical illness this stress response coordinates
endocrine, neural, cardiovascular and immune systems
with the aim to maximize survival chances. The hy-
pothalamus–pituitary–adrenal (HPA) axis, which also
includes elements producing the neurohypophysial hor-
mone arginine–vasopressin (AVP), is one the key
effectors within this system [1]. Relative HPA or AVP
deficiency contributes to cardiovascular collapse in
critically ill patients, leading to the rationale of therapy
with these hormones in shock. Recent developments have
implicated copeptin, a by-product of the AVP precursor,
as a novel biomarker for early stages of critical illness that
could influence clinical decision-making.
Physiology of the HPA axis
A wide variety of circulating local and neurosensory
signals control hypothalamic corticotrophic-releasing
hormone (CRH) and AVP release from the paraven-
tricular nucleus (PVN). Parvocellular neurons co-secrete
CRH and AVP into the hypophysial portal circulation.
These peptides reach the adenohypophysis and synergis-
tically stimulate the release of adrenocorticotrophic
hormone (ACTH). ACTH increases adrenocortical pro-
duction and the release of cortisol, the main
glucocorticoid in humans with widespread homeostatic
effects in many organs. In a recent elegant study, Boo-
nen et al. demonstrated that elevated cortisol levels in
critical illness result from a reduced cortisol metabolism
[2] despite suppressed ACTH and cortisol pulse secre-
tion [3].
AVP is also produced in the magnocellular neurons of
the PVN and directly secreted into the bloodstream through
their axons in the posterior pituitary (Fig. 1a). The principal
effects of circulating AVP are vasoconstriction through its
V1a receptor in vascular smooth muscle cells and water
conservation through renal V2 receptors.
Biomarkers of AVP system
As a stress marker, levels of AVP show a bi-phasic re-
sponse during disease, with an initial rise depending on
disease severity and subsequent decrease. Implementation
of AVP measurements for clinical decision-making in
patients has been hampered by the stability of the peptide,
its binding to platelets and its short half-life of 24 min.
The nonapeptide AVP is cleaved from its precursor pre-
provasopressin together with neurophysin II and copeptin
(Fig. 1b). Copeptin is a glycopeptide with an obscure
function which constitutes the C-terminal 39 amino acids
of preprovasopressin and demonstrates significant sta-
bility ex vivo and even post-mortem [4, 5]. The
development of a one-step sandwich immunoassay for
copeptin has provided the tool for an increasing number
of studies over the last decade into the use of this AVP
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co-secreted peptide as an early marker for osmotic or
hemodynamic dysregulation.
First studied in septic shock patients, copeptin levels
were found to be [400-fold higher in this patient
population than in healthy control subjects [5]. Circulat-
ing copeptin concentrations are also increased in critically
ill patients during early stages of systemic inflammatory
response syndrome, myocardial infarction, heart failure,
stroke or after major surgery and trauma and are associ-
ated with AVP, C-reactive protein and cortisol
concentrations, osmolality and disease severity [4, 6–12].
Copeptin levels at presentation are associated with mor-
tality and have been shown to be additive in prediction
models of survival in patients with septic shock [7, 8],
myocardial infarction [10] and stroke [12]. Moreover,
copeptin is superior to AVP as discriminator between
septic and non-septic patients [13]. Interestingly, the
correlation between AVP and copeptin levels has been
found to dissipate in patients on hemofiltration therapy,
thereby questioning the reliability of copeptin measure-
ment as an adequate marker of the vasopressinergic
system in this patient subgroup [4, 9]. As expected,
copeptin level decreases in the majority of patients treated
with exogenous AVP [14].
In a recent extensive Chinese study of patients pre-
senting to the emergency department with sepsis [15],
copeptin was measured together other stress markers. All
markers showed a step-wise increment according to dis-
ease severity. In the patient population, copeptin, cortisol
and ACTH levels measured at admission were all in-
versely associated with survival, with copeptin having the
highest prognostic value [receiver operating characteris-
tics area under the curve (AUC) of 0.826]. Intriguingly,
the combination of copeptin, cortisol and procalcitonin
concentrations and the Mortality in Emergency Depart-
ment Sepsis (MEDS) score yielded an AUC of 0.891 for
predicting 28-day survival.
Conclusions
Copeptin constitutes a novel and promising biomarker
during the acute phase for disease severity and prognosis
in critically ill patients. Its concentration can distinguish
between sepsis and other causes of critical illness and
appears a superior marker to AVP. Future studies are
needed to delineate whether copeptin measurements are
Fig. 1 a Schematic overview of
the hypothalamus–pituitary–
adrenal (HPA) axis and
arginine–vasopressin (AVP).
Co-secreted corticotrophic-
releasing hormone (CRH) and
AVP from the parvocellular
(P) cells of the paraventricular
nucleus stimulate pituitary
release of adrenocorticotrophic
hormone (ACTH), which in turn
induces cortisol secretion from
the adrenal. Hypothalamic
magnocellular (M) neurons
transport AVP through their
axons to the posterior pituitary
where AVP is secreted in
response to osmotic or
hemodynamic stimuli.
b Precursor molecule of AVP
consisting of four individual
peptides
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cost-effective, add significantly to clinical judgment and
can be utilized for stratification of therapy, particularly
early management of sepsis.
Conflicts of interest The authors have no potential conflict of
interest that could prejudice the impartiality of this scientific work.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits any noncommercial use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Chrousos GP (2000) The stress
response and immune function: clinical
implications. The 1999 Novera H.
Spector Lecture. Ann NY Acad Sci
917:38–67
2. Boonen E, Vervenne H, Meersseman P,
Andrew R, Mortier L, Declercq PE,
Vanwijngaerden YM, Spriet I, Wouters
PJ, Vander Perre S, Langouche L,
Vanhorebeek I, Walker BR, Van den
Berghe G (2013) Reduced cortisol
metabolism during critical illness.
N Engl J Med 368:1477–1488
3. Boonen E, Meersseman P, Vervenne H,
Meyfroidt G, Guiza F, Wouters PJ,
Veldhuis JD, Van den Berghe G (2014)
Reduced nocturnal ACTH-driven
cortisol secretion during critical illness.
Am J Physiol Endocrinol Metab
306:E883–E892
4. Jochberger S, Velik-Salchner C, Mayr
VD, Luckner G, Wenzel V,
Falkensammer G, Ulmer H,
Morgenthaler N, Hasibeder W, Dunser
MW (2009) The vasopressin and
copeptin response in patients with
vasodilatory shock after cardiac
surgery: a prospective, controlled study.
Intensive Care Med 35:489–497
5. Struck J, Morgenthaler NG, Bergmann
A (2005) Copeptin, a stable peptide
derived from the vasopressin precursor,
is elevated in serum of sepsis patients.
Peptides 26:2500–2504
6. Jochberger S, Morgenthaler NG, Mayr
VD, Luckner G, Wenzel V, Ulmer H,
Schwarz S, Hasibeder WR,
Friesenecker BE, Dunser MW (2006)
Copeptin and arginine vasopressin
concentrations in critically ill patients.
J Clin Endocrinol Metab 91:4381–4386
7. Morgenthaler NG, Muller B, Struck J,
Bergmann A, Redl H, Christ-Crain M
(2007) Copeptin, a stable peptide of the
arginine vasopressin precursor, is
elevated in hemorrhagic and septic
shock. Shock 28:219–226
8. Seligman R, Papassotiriou J,
Morgenthaler NG, Meisner M, Teixeira
PJ (2008) Copeptin, a novel prognostic
biomarker in ventilator-associated
pneumonia. Crit Care 12:R11
9. Jochberger S, Zitt M, Luckner G, Mayr
VD, Wenzel V, Ulmer H, Morgenthaler
NG, Hasibeder WR, Dunser MW
(2009) Postoperative vasopressin and
copeptin levels in noncardiac surgery
patients: a prospective controlled trial.
Shock 31:132–138
10. Lipinski MJ, Escarcega RO, D’Ascenzo
F, Magalhaes MA, Baker NC, Torguson
R, Chen F, Epstein SE, Miro O, Llorens
P, Giannitsis E, Lotze U, Lefebvre S,
Sebbane M, Cristol JP, Chenevier-
Gobeaux C, Meune C, Eggers KM,
Charpentier S, Twerenbold R, Mueller
C, Biondi-Zoccai G, Waksman R
(2014) A systematic review and
collaborative meta-analysis to
determine the incremental value of
copeptin for rapid rule-out of acute
myocardial infarction. Am J Cardiol
113:1581–1591
11. Westermann I, Dunser MW, Haas T,
Jochberger S, Luckner G, Mayr VD,
Wenzel V, Stadlbauer KH, Innerhofer
P, Morgenthaler N, Hasibeder WR,
Voelckel WG (2007) Endogenous
vasopressin and copeptin response in
multiple trauma patients. Shock
28:644–649
12. De Marchis GM, Katan M, Weck A,
Fluri F, Foerch C, Findling O, Schuetz
P, Buhl D, El-Koussy M, Gensicke H,
Seiler M, Morgenthaler N, Mattle HP,
Mueller B, Christ-Crain M, Arnold M
(2013) Copeptin adds prognostic
information after ischemic stroke:
results from the CoRisk study.
Neurology 80:1278–1286
13. Lesur O, Roussy JF, Chagnon F, Gallo-
Payet N, Dumaine R, Sarret P, Chraibi
A, Chouinard L, Hogue B (2010)
Proven infection-related sepsis induces
a differential stress response early after
ICU admission. Crit Care 14:R131
14. Torgersen C, Luckner G, Morgenthaler
NG, Jochberger S, Schmittinger CA,
Wenzel V, Hasibeder WR, Grander W,
Dunser MW (2010) Plasma copeptin
levels before and during exogenous
arginine vasopressin infusion in patients
with advanced vasodilatory shock.
Minerva Anestesiol 76:905–912
15. Zhang Q, Dong G, Zhao X, Wang M, Li
CS (2014) Prognostic significance of
hypothalamic–pituitary–adrenal axis
hormones in early sepsis: a study
performed in the emergency
department. Intensive Care Med
40:1499–1508
1479
